2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Gynecologic
1
Dermatologic
1
Conditions
Keratosis, Actinic
7
Neoplasms
5
Melanoma
3
Warts
2
Prostatic Neoplasms
2
Neoplasm Metastasis
2
Hyperthermia
2
Hematologic Neoplasms
2
Hemangioma
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Tuberous Sclerosis
1
Squamous Intraepithelial Lesions
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors Harboring NTRK Fusion
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Seizures
1
Sarcoma
1
Recurrence
1
Rectal Neoplasms
1
Polycystic Ovary Syndrome
1
Pituitary Neoplasms
1
Pelvic Neoplasms
1
Pain
1
Ovarian Neoplasms
1
Obesity
1
Nonmelanoma Skin Cancers
1
Mucositis
1
Interventions
Cyclophosphamide
32
Etoposide
18
romidepsin
17
fludarabine
17
Vincristine
17
Doxorubicin
16
Rituximab
14
Prednisone
14
Melphalan
14
Gemcitabine
13
Brentuximab Vedotin
13
Lenalidomide
12
Peripheral Blood Stem Cell Transplantation
11
Cytarabine
11
Whole-Body Irradiation
10
Biopsy
10
10-propargyl-10-deazaaminopterin
10
pembrolizumab
9
fludarabine phosphate
9
Specimen Handling
9
Busulfan
9
Mycophenolic Acid
8
Granulocyte Colony-Stimulating Factor
8
Depsipeptides
8
Carmustine
8
Bortezomib
8
duvelisib
7
Vorinostat
7
Methotrexate
7
Magnetic Resonance Spectroscopy
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, T-Cell
×
Solutions
×
Clear all
NCT04752826
2026-02-18
MK-3475-D20
BioInvent International AB
Phase 1/2
Recruiting
176 enrolled